Daily oral GLP-1 medication shows similar weight loss across menopausal stages

New research presented at the European Association for the Study of Diabetes annual meeting demonstrates that orforglipron, a daily oral GLP-1 medication for weight loss and type 2 diabetes management, produces comparable weight loss results in women across all menopausal stages—before, during, and after menopause. This finding is significant because it suggests that hormonal changes associated with menopause do not substantially impact the medication's effectiveness for weight management. The results indicate that women at different life stages can benefit equally from this treatment option, potentially improving access to effective weight management solutions for a broader population.